Skip to main content
Displaying 25 - 36 of 71
Display:
12
24
48
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
General Hepatology
4
Gore & Associates: Small TIPS for the right reason, right patient at the right time - ILC 2022
View
General Hepatology
4
Gore & Associates: Small TIPS for the right reason, right patient at the right time - ILC 2022
View
General Hepatology
4
Gore & Associates: Small TIPS for the right reason, right patient at the right time - ILC 2022
View
General Hepatology
4
Gore & Associates: Small TIPS for the right reason, right patient at the right time - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Pagination
First page
« First
Previous page
‹ previous
Page
1
Page
2
Current page
3
Page
4
Page
5
Page
6
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy